Share Twitter LinkedIn Facebook Email James L. Gulley, MD, PhD, FACP, National Cancer Institute, explains M7824 – Novel Bifunctional Protein | Anti-Body Targeting PD-L1, Sequester TGF-? at Annual Meeting 2018
Inotuzumab Ozogamicin and Gemtuzumab Ozogamicin: A 2024 Guide to Managing Liver Toxicity and Cancer Treatment for Oncologists [40 Slides] Hematologic Malignancies 5 Mins Read
Non-Malignant Hematology Clinics: Essential Pioneers in the Evolving Hematologic Care Hematologic Malignancies 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read